Abstract
Introduction
The expression of E-cadherin, β-catenin and topoisomerase II has been associated with clinical outcome of several cancers including sarcomas. We aimed to evaluate the expression of these markers in leiomyosarcomas (LMS).
Materials and methods
Paraffin blocks of 19 primary, nonmetastatic LMS were analysed immunohistochemically for the expression of the above-mentioned markers with a cutoff level for positivity of 20% of cell staining.
Results
Expression of E-cadherin was negative in all LMS. Nuclear expression of β-catenin was also negative in all cases, while positive cytoplasmic β-catenin expression was observed in approximately half of the patients. The majority of LMS had expression of topoisomerase IIα, although only in 10 patients was this expression in more than 20% of tumour cells. From the analysed factors, tumour size was statistically significantly correlated with relapse-free survival.
Conclusions
Further evidence with larger series is required in order to determine the implication of these markers in LMS.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451–1455
Halbleib JM, Nelson WJ (2006) Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 20:3199–3214
Muller S, Su L, Tighiouart M et al (2008) Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 113:97–107
Miyanaga A, Gemma A, Ando M et al (2008) E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep 19:377–383
Saito T, Oda Y, Sakamoto A et al (2000) Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 192:342–350
Ng TL, Gown AM, Barry TS et al (2005) Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18:68–74
Ilyas M, Tomlinson IP (1997) The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J Pathol 182:128–137
van Es JH, Barker N, Clevers H (2003) You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13:28–33
Iino K, Sasano H, Yabuki N et al (1997) DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 10:901–907
Tanoguchi K, Sasano H, Yabuki N et al (1998) Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Mod Pathol 11:186–193
Depowski PL, Rosenthal SI, Brien TP et al (2000) Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 13:542–547
Larbcharoensub N, Leopairat J, Sirachainan E et al (2008) Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39:837–845
Haber M, Smith J, Bordow SB et al (2006) Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24:1546–1453
Yoo J, Park S, Kang CS et al (2008) Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med 126:33–38
Sato H, Hasegawa T, Abe Y et al (1999) Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol 30:1344–1349
Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C et al (2005) Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 29:653–659
Carlson JW, Fletcher CD (2007) Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 51:509–514
Hasegawa T, Yokoyama R, Matsuno Y et al (2001) Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 32:257–263
Gaumann A, Tews DS, Mentzel T et al (2003) Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch 442:529–537
Endo H, Hirokawa M, Ishimaru N et al (2004) Unique cell membrane expression of topoisomerase-II alpha as a useful diagnostic marker of liposarcoma. Pathol Int 54:145–150
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gogou, P.N., Batistatou, A., Pakos, E.E. et al. Expression of E-cadherin, β-catenin and topoisomerase IIα in leiomyosarcomas. Clin Transl Oncol 11, 548–551 (2009). https://doi.org/10.1007/s12094-009-0401-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-009-0401-3